{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:26Z","timestamp":1793744726838,"version":"4.6.1"},"reference-count":78,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adoptive immunotherapy using B-cell\u2013targeted chimeric antigen receptor (CAR)-modified T cells to treat hematologic malignancies is transforming cancer care for patients with refractory or relapsed diseases. Recent and anticipated regulatory approval for products targeting acute lymphoblastic leukemia, lymphomas, and multiple myeloma have led to global implementation of these novel treatments. The rapidity of commercial utilization of CAR\u2013T-cell therapy has created a largely unexplored gap in patient supportive-care approaches. Such approaches are critical in these complex patients given their high net state of immunosuppression prior to CAR\u2013T-cell infusion coupled with unique acute and persistent insults to their immune function after CAR\u2013T-cell infusion. In this \u201cHow I Treat\u201d article, we focus on key questions that arise during 3 phases of management for patients receiving CD19-targeted CAR-T cells: pre CAR\u2013T-cell infusion, immediate post CAR\u2013T-cell infusion, and long-term follow-up. A longitudinal patient case is presented for each phase to highlight fundamental issues including infectious diseases screening, antimicrobial prophylaxis, immunoglobulin supplementation, risk factors for infection, and vaccination. We hope this discussion will provide a framework for institutions and health care providers to formulate their own approach to preventing infections in light of the paucity of data specific to this treatment modality.<\/jats:p>","DOI":"10.1182\/blood.2019004000","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T23:59:42Z","timestamp":1593043182000},"page":"925-935","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":303,"title":["How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division,"},{"name":"Clinical Research Division, and"},{"name":"Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Seo","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"26","key":"2020082011244632700_B1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020082011244632700_B2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020082011244632700_B3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2020082011244632700_B4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2020082011244632700_B5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020082011244632700_B6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2020082011244632700_B7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020082011244632700_B8","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020082011244632700_B9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020082011244632700_B10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"5","key":"2020082011244632700_B11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2020082011244632700_B12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"7","key":"2020082011244632700_B13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood.2018883421","article-title":"CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"134","author":"Sauter","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2020082011244632700_B14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2020082011244632700_B15","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"355","key":"2020082011244632700_B16","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"8","key":"2020082011244632700_B17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"2020082011244632700_B18","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020082011244632700_B19","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2020082011244632700_B20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2020082011244632700_B21","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020082011244632700_B22","first-page":"635","article-title":"Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis","volume":"64","author":"Cheng","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2020082011244632700_B23","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"2020082011244632700_B24","doi-asserted-by":"crossref","first-page":"e0132426","DOI":"10.1371\/journal.pone.0132426","article-title":"Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis","volume":"10","author":"Shih","year":"2015","journal-title":"PLoS One"},{"issue":"26","key":"2020082011244632700_B25","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020082011244632700_B26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/QCO.0000000000000500","article-title":"Hepatitis B virus and hepatitis C virus infection in immunocompromised patients","volume":"31","author":"Hwang","year":"2018","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"2020082011244632700_B27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s40425-019-0790-y","article-title":"Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma","volume":"7","author":"Wei","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2020082011244632700_B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"21","key":"2020082011244632700_B29","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"issue":"22","key":"2020082011244632700_B30","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2020082011244632700_B31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"issue":"6638","key":"2020082011244632700_B32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"issue":"3","key":"2020082011244632700_B33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"482","key":"2020082011244632700_B34","doi-asserted-by":"crossref","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"2020082011244632700_B35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Blood Marrow Transplant. 2010;16(2):294]","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020082011244632700_B36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I","article-title":"Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life","volume":"31","author":"Pihlgren","year":"2001","journal-title":"Eur J Immunol"},{"issue":"5","key":"2020082011244632700_B37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020082011244632700_B38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020082011244632700_B39","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbmt.2018.01.017","article-title":"Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group\u2019s list of 5 tests and treatments to question in blood and marrow transplantation","volume":"24","author":"Bhella","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020082011244632700_B40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"issue":"1","key":"2020082011244632700_B41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"2020082011244632700_B42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"2020082011244632700_B43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","article-title":"Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival","volume":"41","author":"Norlin","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2020082011244632700_B44","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"key":"2020082011244632700_B45","volume-title":"Diagnostic & Clinical Care Guidelines for Primary Immunodeficiency Diseases","author":"Buckley","year":"2015","edition":"ed"},{"issue":"5","key":"2020082011244632700_B46","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 3","key":"2020082011244632700_B47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2020082011244632700_B48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","article-title":"Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation","volume":"32","author":"Ueda","year":"2018","journal-title":"Blood Rev"},{"key":"2020082011244632700_B49","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"2020082011244632700_B50","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2020082011244632700_B51","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.bbmt.2018.12.575","article-title":"Infectious complications following CD19 CAR T cell immunotherapy for children and young adults with refractory ALL","volume":"25","author":"Vora","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020082011244632700_B52","article-title":"Invasive mold infections after chimeric antigen receptor-modified t-cell therapy: a case series, review of the literature, and implications for prophylaxis [published online ahead of print 22 November 2019]","author":"Haidar","journal-title":"Clin Infect Dis"},{"issue":"21","key":"2020082011244632700_B53","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020082011244632700_B54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2017-11-812982","article-title":"CD19 CAR-T therapy and sepsis: dancing with the devil","volume":"131","author":"Budde","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2020082011244632700_B55","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/bloodadvances.2019000717","article-title":"Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2020082011244632700_B56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2020082011244632700_B57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2020082011244632700_B58","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2020082011244632700_B59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"23","key":"2020082011244632700_B60","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020082011244632700_B61","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2020082011244632700_B62","doi-asserted-by":"crossref","first-page":"E188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2020082011244632700_B63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2020082011244632700_B64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2020082011244632700_B65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"issue":"10","key":"2020082011244632700_B66","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"9","key":"2020082011244632700_B67","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/bmt.2009.364","article-title":"Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant","volume":"45","author":"Cordonnier","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020082011244632700_B68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbmt.2004.12.330","article-title":"Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation","volume":"11","author":"Antin","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2020082011244632700_B69","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020082011244632700_B70","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1080\/10428194.2017.1393668","article-title":"CAR T cell therapy for multiple myeloma: where are we now and where are we headed?","volume":"59","author":"Ghosh","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2020082011244632700_B71","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2020082011244632700_B72","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020082011244632700_B73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"issue":"suppl 4","key":"2020082011244632700_B74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ajt.12094","article-title":"Screening of donor and recipient in solid organ transplantation","volume":"13","author":"Fischer","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"2020082011244632700_B75","doi-asserted-by":"crossref","first-page":"ofx170","DOI":"10.1093\/ofid\/ofx170","article-title":"Characterizing cefepime neurotoxicity: a systematic review","volume":"4","author":"Appa","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2020082011244632700_B76","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"2020082011244632700_B77","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2020082011244632700_B78","unstructured":"Fred\n              Hutchinson\n            \n          . Cellular Immunotherapy LTFU.https:\/\/www.fredhutch.org\/en\/research\/patient-treatment-support\/long-term-follow-up\/cellular-immunotherapy-ltfu.html. Accessed 21 April 2020."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/8\/925\/1755391\/bloodbld2019004000c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/8\/925\/1755391\/bloodbld2019004000c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T11:54:15Z","timestamp":1597924455000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/8\/925\/461120\/How-I-prevent-infections-in-patients-receiving"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004000","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}